Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism DYRK1A inhibitors(Dual-specificity tyrosine-phosphorylation regulated kinase 1A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC18H22N4O2S |
InChIKeyCHQYAWLKOUOTQO-QVYJARAXSA-N |
CAS Registry2732859-75-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Phase 1 | FR | Perha PharmaceuticalsStartup | 18 Jan 2024 |
Down Syndrome | Phase 1 | FR | Perha PharmaceuticalsStartup | 18 Jan 2024 |
Cognition Disorders | Preclinical | FR | 16 Nov 2023 |